thalidomide has been researched along with Chronic Bullous Disease of Childhood in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Maione, V | 3 |
Bettolini, L | 3 |
Venturuzzo, A | 3 |
Tonon, F | 3 |
Battocchio, S | 3 |
Calzavara-Pinton, P | 3 |
Lu, Z | 1 |
Su, D | 1 |
Li, X | 1 |
Da, Z | 1 |
2 other studies available for thalidomide and Chronic Bullous Disease of Childhood
Article | Year |
---|---|
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide | 2023 |
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide | 2023 |
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide | 2023 |
Efficacy of apremilast in a case of resistant linear IgA bullous disease.
Topics: Humans; Immunoglobulin A; Linear IgA Bullous Dermatosis; Skin Diseases, Vesiculobullous; Thalidomide | 2023 |
LABD-like manifestation in a patient with systemic lupus erythematosus.
Topics: Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Linear IgA Bullous Derm | 2021 |